Log in

Relevant bibliographies by topics / Neoadjuvant chemotherapy (NAC) / Journal articles

To see the other types of publications on this topic, follow the link: Neoadjuvant chemotherapy (NAC).

Journal articles on the topic 'Neoadjuvant chemotherapy (NAC)'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Neoadjuvant chemotherapy (NAC).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wang, Dong, Jiafu Feng, and Bei Xu. "A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer." Future Oncology 15, no. 23 (2019): 2779–90. http://dx.doi.org/10.2217/fon-2019-0165.

Full text

Abstract:

Aim: Platinum agents are DNA damaging agents with promising activity in breast cancers, especially in triple-negative subgroup. This meta-analysis was conducted to compare the treatments of platinum-based neoadjuvant chemotherapy (NAC) and standard NAC for triple-negative breast cancers (TNBCs). Materials & methods: Diverse electronic databases were searched to identify the randomized clinical trials that directly compared the treatments of platinum-based NAC versus NAC in TNBC patients. Toxicity of platinum-based regimens was further evaluated. Results: Addition of platinum agents signifi

APA, Harvard, Vancouver, ISO, and other styles

2

Gusic, Lejla Hadzikadic, Kendall Walsh, Teresa Flippo-Morton, Terry Sarantou, Danielle Boselli, and Richard L. White. "Rationale for Mastectomy after Neoadjuvant Chemotherapy." American Surgeon 84, no. 1 (2018): 126–32. http://dx.doi.org/10.1177/000313481808400133.

Full text

Abstract:

Neoadjuvant chemotherapy (NAC) reduces tumor size, facilitating the use of breast conservation surgery (BCS). However, mastectomy remains the surgical outcome for certain women. The goal of this study was to determine the rationale for mastectomy after NAC, particularly in women eligible for BCS. Retrospective data were reviewed on patients who received NAC between February 2006 and August 2010 at our institution. Demographics and tumor characteristics were compared between patients who received BCS and mastectomy after NAC. Of 149 patients meeting inclusion criteria, 102 (68%) underwent BCS a

APA, Harvard, Vancouver, ISO, and other styles

3

Murakawa, Masaaki, Daishi Takahashi, Shinnosuke Kawahara, et al. "Clinical therapeutic effects of neoadjuvant chemotherapy in resectable pancreatic cancer." Journal of Clinical Oncology 41, no. 4_suppl (2023): 677. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.677.

Full text

Abstract:

677 Background: Results from the phase III Prep-02/JSAP-05 trial demonstrated the efficacy and safety of gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer. However, consensus on neoadjuvant chemotherapy for pancreatic cancer has not yet been established, and the effects of neoadjuvant therapy on clinical features of the tumor and improvement in prognosis have not been fully investigated. We aimed to investigate the effect of neoadjuvant chemotherapy on resectable pancreatic cancer. Methods: Between 2013 and 2021, 291 patients who underwent curative resection for

APA, Harvard, Vancouver, ISO, and other styles

4

Cai, Changjing, Ying Han, Yinghui Peng, et al. "The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer." Journal of Clinical Oncology 42, no. 16_suppl (2024): e15621-e15621. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15621.

Full text

Abstract:

e15621 Background: The recurrence rate of locally advanced colon cancer (T3-4 or N+, M0) after surgery is significantly high. Emerging data indicate that the combination of immunotherapy and chemotherapy demonstrates synergistic effects in other solid tumors. Consequently, a combination of immunotherapy and chemotherapy holds the potential to benefit patients with MSS and pMMR colon cancer. We have designed a prospective trial to investigate whether the immune checkpoint inhibitor (ICI) in combination with chemotherapy represents a safe and beneficial treatment approach for locally advanced co

APA, Harvard, Vancouver, ISO, and other styles

5

Robova, Helena, Michael Halaska, Marek Pluta, et al. "The Role of Neoadjuvant Chemotherapy and Surgery in Cervical Cancer." International Journal of Gynecologic Cancer 20, Suppl 2 (2010): S42—S46. http://dx.doi.org/10.1111/igc.0b013e3181f60d73.

Full text

Abstract:

The role of neoadjuvant chemotherapy (NAC) in "bulky" and locally advanced cervical cancer has been of interest for the last 25 years, and in many countries, NAC has become the standard of care. In the present paper, we review our 10 years' experience with high-dose-density NAC in cervical cancer management in 141 women (CervNAC I protocol). High-dose-density neoadjuvant chemotherapy and radical surgery has resulted in high clinical response rates and seems to be feasible in the management of stage IB bulky cervical cancer. Neoadjuvant chemotherapy reduces tumor volume and positivity of lymph

APA, Harvard, Vancouver, ISO, and other styles

6

Körner, Stefanie Korsgaard, Thomas Dreyer, Andreas Carus, et al. "DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer." Scandinavian Journal of Urology 59 (February 26, 2024): 39–46. http://dx.doi.org/10.2340/sju.v59.24024.

Full text

Abstract:

Objective: To investigate the impact of neoadjuvant chemotherapy implementation with gemcitabine-cisplatin on survival outcomes for patients with muscle-invasive bladder cancer in Denmark. Materials and Methods: Data were collected on all patients in Denmark undergoing radical cystectomy who were potential candidates for neoadjuvant chemotherapy from 2010 to 2015 (n = 851). A cohort before the implementation of neoadjuvant chemotherapy (Cohort 2010–12) was compared with a cohort after implementation (Cohort 2013–15). Patients in Cohort 2013–15 receiving neoadjuvant chemotherapy (+NAC, n = 213)

APA, Harvard, Vancouver, ISO, and other styles

7

Ayaz, Ahsan, Syed Arsalan Ahmed Naqvi, Nikita Tripathi, et al. "Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis." Journal of Clinical Oncology 41, no. 6_suppl (2023): 531. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.531.

Full text

Abstract:

531 Background: Neoadjuvant cisplatin-based chemotherapy (NAC) is established in the management of MIBC. Pathologic complete response (pCR, ypT0N0) and downstaging (<ypT2N0) are associated with long term survival in patients with MIBC. Several trials have evaluated neoadjuvant immunotherapy (NAI) and chemoimmunotherapy (NACI) for MIBC. We aimed to conduct a meta-analysis of available trials to compare the incidence of pathological response with NAC, NAI and NACI in MIBC patients undergoing radical cystectomy. Methods: Phase II/III clinical trials assessing neoadjuvant systemic therapies (NA

APA, Harvard, Vancouver, ISO, and other styles

8

Macedo, Francis Igor, Kristin Kelly, Danny Yakoub, Dido Franceschi, Alan S. Livingstone, and Nipun B. Merchant. "Utility of radiation after neoadjuvant chemotherapy for surgically resectable esophageal cancer." Journal of Clinical Oncology 37, no. 4_suppl (2019): 172. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.172.

Full text

Abstract:

172 Background: Neoadjuvant chemotherapy (NAC) is the gold standard approach for locally advanced esophageal cancer (EC), however the addition of radiation remains largely controversial. We sought to investigate the role of neoadjuvant radiation in resectable EC by comparing outcomes of patients who underwent neoadjuvant chemotherapy with (NACR) or without radiation (NAC) using a large nationwide cohort. Methods: National Cancer Data Base (NCDB) was queried for patients with non-metastatic EC between 2010 and 2014. Kaplan-Meier, log-rank and Cox multivariable regression analysis were performed

APA, Harvard, Vancouver, ISO, and other styles

9

Matsumoto, Takuya, Suguru Hasegawa, Masazumi Zaima, Naoya Inoue, and Yoshiharu Sakai. "Outcomes of Neoadjuvant Chemotherapy without Radiation for Rectal Cancer." Digestive Surgery 32, no. 4 (2015): 275–83. http://dx.doi.org/10.1159/000430469.

Full text

Abstract:

Aim: The efficacy of neoadjuvant chemotherapy without radiation (NAC) in the treatment of rectal cancer remains unclear. This retrospective study was aimed at determining the pathological complete response rate and short-term outcomes of NAC in patients with locally advanced rectal cancer. Patients and Methods: We collected data on 159 consecutive patients treated for rectal cancer (cT3/cT4a, cN+, and cM0 status) at five tertiary referral hospitals between 2005 and 2010. Pathological complete response (pCR) and safety were assessed as the main outcomes in 124 eligible patients comprising 15 wh

APA, Harvard, Vancouver, ISO, and other styles

10

Holt, Anouchka Coste, Maurice Berkowitz, Nicholas McAndrew, Courtney Smith, Jennifer Baker, and Nimmi Kapoor. "Abstract PO2-22-10: Surgical outcomes after neoadjuvant chemotherapy with and without immunotherapy in patients with triple negative breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO2–22–10—PO2–22–10. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-22-10.

Full text

Abstract:

Abstract Background: The KEYNOTE-522 trial demonstrated that the addition of neoadjuvant pembrolizumab to neoadjuvant chemotherapy (NAC) for the treatment of early-stage triple negative breast cancer (TNBC) significantly improves rates of both pathologic complete response (pCR) and event-free survival. The impact of adding immunotherapy to NAC on surgical outcomes, however, is unknown. The purpose of this study is to compare 90-day surgical complication rates and timing to subsequent adjuvant therapy of patients undergoing neoadjuvant chemotherapy for stage I-III TNBC with and without immunoth

APA, Harvard, Vancouver, ISO, and other styles

11

Rho, M., M. Materazzo, A. Antonelli, et al. "Breast reconstruction following Neoadjuvant Chemotherapy (NAC)." Breast 44 (March 2019): S116—S117. http://dx.doi.org/10.1016/s0960-9776(19)30392-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Brönimann, Stephan, David D’Andrea, Shahrokh F. Shariat, and Kilian M. Gust. "Neoadjuvant therapy in urothelial cancer." memo - Magazine of European Medical Oncology 12, no. 4 (2019): 329–33. http://dx.doi.org/10.1007/s12254-019-00533-8.

Full text

Abstract:

Summary Neoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level 1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant chemotherapy (NAC), acceptance rates are still low. In high-risk upper tract urothelial cancer (UTUC), cumulative evidence suggests that NAC for locally advanced UTUC can improve oncological outcome. Ongoing phase 3 trials will finally prove the benefit or futility of NAC in this tumor entity. Since urothelial cancer (UC) is a heterogeneous disease

APA, Harvard, Vancouver, ISO, and other styles

13

Asaoka, Mariko, Shipra Gandhi, Takashi Ishikawa, and Kazuaki Takabe. "Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future." Breast Cancer: Basic and Clinical Research 14 (January 2020): 117822342098037. http://dx.doi.org/10.1177/1178223420980377.

Full text

Abstract:

Neoadjuvant chemotherapy (NAC) had been developed as a systematic approach before definitive surgery for the treatment of locally advanced or inoperable breast cancer such as inflammatory breast cancer in the past. In addition to its impact on surgery, the neoadjuvant setting has a benefit of providing the opportunity to monitor the individual drug response. Currently, the subject of NAC has expanded to include patients with early-stage, operable breast cancer because it is revealed that the achievement of a pathologic complete response (pCR) is associated with excellent long-term outcomes, es

APA, Harvard, Vancouver, ISO, and other styles

14

Seager, Robert J., Heidi Ko, Sarabjot Pabla, et al. "Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer." Journal of Personalized Medicine 14, no. 5 (2024): 481. http://dx.doi.org/10.3390/jpm14050481.

Full text

Abstract:

Background: KEYNOTE-522 resulted in FDA approval of the immune checkpoint inhibitor pembrolizumab in combination with neoadjuvant chemotherapy for patients with early-stage, high-risk, triple-negative breast cancer (TNBC). Unfortunately, pembrolizumab is associated with several immune-related adverse events (irAEs). We aimed to identify potential tumor microenvironment (TME) biomarkers which could predict patients who may attain pathological complete response (pCR) with chemotherapy alone and be spared the use of anti-PD-1 immunotherapy. Methods: Comprehensive immune profiling, including RNA-s

APA, Harvard, Vancouver, ISO, and other styles

15

Liu, Zhaoyun, Bo Yu, Mu Su, et al. "Construction of a model for evaluating the efficacy of neoadjuvant chemotherapy for breast cancer and dynamic monitoring of ctDNA response to neoadjuvant chemotherapy." Journal of Clinical Oncology 40, no. 16_suppl (2022): e12600-e12600. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e12600.

Full text

Abstract:

e12600 Background: Neoadjuvant chemotherapy (NAC) is a routine treatment of choice for patients with locally advanced breast cancer. The pathological complete response (pCR) to NAC in breast cancer is closely related to a better prognosis. In addition, there have been few studies of the role of ctDNA in the dynamic monitoring of NAC, so we explored the prediction model of NAC to predict pCR and evaluated the role of ctDNA in the dynamic monitoring of NAC. Methods: A total of 269 breast cancer patients receiving NAC were enrolled, and a total of 266 tissue samples were collected. The tissue sam

APA, Harvard, Vancouver, ISO, and other styles

16

Liu, Zhaoyun, Bo Yu, Mu Su, et al. "Construction of a model for evaluating the efficacy of neoadjuvant chemotherapy for breast cancer and dynamic monitoring of ctDNA response to neoadjuvant chemotherapy." Journal of Clinical Oncology 40, no. 16_suppl (2022): e12600-e12600. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e12600.

Full text

Abstract:

e12600 Background: Neoadjuvant chemotherapy (NAC) is a routine treatment of choice for patients with locally advanced breast cancer. The pathological complete response (pCR) to NAC in breast cancer is closely related to a better prognosis. In addition, there have been few studies of the role of ctDNA in the dynamic monitoring of NAC, so we explored the prediction model of NAC to predict pCR and evaluated the role of ctDNA in the dynamic monitoring of NAC. Methods: A total of 269 breast cancer patients receiving NAC were enrolled, and a total of 266 tissue samples were collected. The tissue sam

APA, Harvard, Vancouver, ISO, and other styles

17

Branko, Fariza Hakim Rio, and Tomy Lesmana. "C-Reactive Protein (CRP)/Albumin Ratio (CAR) pre-treatment as a predictive factor of radiological response after neoadjuvant chemotherapy in Locally Advanced Rectal Cancer (LARC) patients at Dr. Soetomo General Hospital, Surabaya, Indonesia." Bali Medical Journal 11, no. 1 (2022): 50–55. http://dx.doi.org/10.15562/bmj.v11i1.3004.

Full text

Abstract:

Background: Several serum inflammatory markers have been investigated as prognostic biomarkers for rectal cancer patients, including C-Reactive Protein (CRP)/Albumin Ratio (CAR). We aimed to examine the association between the CAR pre-therapy value and radiological response after neoadjuvant chemotherapyMethods: We recruited locally advanced rectal cancer patients who underwent FOLFOX first-line neoadjuvant chemotherapy (NAC) at Dr. Soetomo General Hospital (Surabaya, Indonesia) from January 2015 to December 2020. Before neoadjuvant chemotherapy treatment, the C-reactive protein (CRP) and albu

APA, Harvard, Vancouver, ISO, and other styles

18

Greenleaf, Erin, Christopher S. Hollenbeak, and Joyce Wong. "Response to neoadjuvant chemotherapy and impact on survival for resected gastric cancer." Journal of Clinical Oncology 34, no. 4_suppl (2016): 122. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.122.

Full text

Abstract:

122 Background: This study assesses the survival impact of perioperative chemotherapy, with further analysis of pathologic response to neoadjuvant chemotherapy (NAC), in patients undergoing gastrectomy for gastric cancer (GC) in a large US sample. Methods: Using the 2003-2012 ACS National Cancer Database, 16,128 patients underwent gastrectomy for cancer. Treatment groups were categorized as: NAC, adjuvant chemotherapy, and surgery only. Patients receiving NAC were further categorized as: down-staged, no response, and disease progression. Univariate and multivariate analyses were performed to e

APA, Harvard, Vancouver, ISO, and other styles

19

Yan, Jingrui, Tianxing Zhou, Chao Yang, Yongjie Xie, Jun Yu, and Jihui Hao. "Abstract 6433: Anti-CD36 monoclonal antibody can sensitize the neoadjuvant chemotherapy response in PDAC by eliminating the senescent tertiary lymphatic structure." Cancer Research 84, no. 6_Supplement (2024): 6433. http://dx.doi.org/10.1158/1538-7445.am2024-6433.

Full text

Abstract:

Abstract Objective: Pancreatic ductal adenocarcinoma (PDAC) is deadly and aggressive. Neoadjuvant chemotherapy (NAC) may reduce tumor volume and alter the resectability of the tumor. The efficacy of neoadjuvant chemotherapy in patients is still limited. Tertiary lymphoid structures (TLSs) develop in peripheral non-lymphoid tissues and are essential for the immune response and correlate with chemotherapy in various tumor types. However, more research is needed to determine how TLSs affect neoadjuvant chemotherapy in PDAC. We aim to determine how neoadjuvant chemotherapy affects tumor-infiltrati

APA, Harvard, Vancouver, ISO, and other styles

20

Wimmer, K., M. Sachet, R. Exner, F. Fitzal, M. Filipits, and R. Oehler. "P06.08 Immunomodulatory biomarkers in neoadjuvant chemotherapy of breast cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 2 (2020): A44.3—A45. http://dx.doi.org/10.1136/jitc-2020-itoc7.87.

Full text

Abstract:

BackgroundNeoadjuvant chemotherapy (NAC) with epirubicin/cyclophosphamid followed by docetaxel (E/C->D) is currently one standard-of-care therapy option in women with early, high-risk or locally advanced breast cancer. While some patients respond excellently to preoperative therapy, in other patients significant tumor shrinkage cannot be achieved. We investigated the impact of NAC on circulating immunomodulatory parameters. We also examined whether changes in these parameters correlate with the response to NAC measured by the Residual Cancer Burden (RCB) score determined after neoadjuvant t

APA, Harvard, Vancouver, ISO, and other styles

21

Glover, Michael, Agnes Ewongwo, Melissa Usoz, et al. "Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC." Journal of Clinical Oncology 42, no. 4_suppl (2024): 577. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.577.

Full text

Abstract:

577 Background: Trimodality bladder preservation is an acceptable alternative to radical cystectomy (RC) for muscle invasive bladder cancer (MIBC). Multiple retrospective studies have reported similar disease control rates and overall survival rates with chemoradiation (CRT), but the benefit of neoadjuvant chemotherapy (NAC) prior to CRT is not established. This study investigates the outcomes of CRT with or without NAC for management of MIBC. Methods: Retrospective analysis of 135 adult patients with muscle invasive bladder cancer evaluated in the Department of Radiation Oncology over 7 years

APA, Harvard, Vancouver, ISO, and other styles

22

Tsubosa, Yasuhiro, Masahiro Niihara, Satoru Matsuda, et al. "Comparison of radical surgery followed by adjuvant chemotherapy with radical surgery following neoadjuvant chemotherapy as initial treatment for patients with locally advanced thoracic esophageal squamous cell carcinoma." Journal of Clinical Oncology 33, no. 3_suppl (2015): 187. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.187.

Full text

Abstract:

187 Background: Although radical surgery with neoadjuvant chemotherapy (NAC) is a standard therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC) in response to the result of JCOG 9907 study in Japan, there was no significant difference in survival rate at adjuvant chemotherapy and neoadjuvant chemotherapy in cStage III at subanalysis. Methods: Consecutive patients histologically diagnosed with ESCC and planned to undergo radical surgery followed by adjuvant chemotherapy (ADJ) from September 2002 to April 2007 and radical surgery following NAC from May 2007 to December

APA, Harvard, Vancouver, ISO, and other styles

23

Chanenchuk, Tori, Samantha M. Thomas, Astrid Botty van den Bruele, et al. "Abstract P2-12-01: Survival Outcomes after Pathologic Complete Response with Neoadjuvant Endocrine Therapy vs. Neoadjuvant Chemotherapy." Clinical Cancer Research 31, no. 12_Supplement (2025): P2–12–01—P2–12–01. https://doi.org/10.1158/1557-3265.sabcs24-p2-12-01.

Full text

Abstract:

Abstract Background: Neoadjuvant systemic therapy has emerged as the standard of care for many patients with breast cancer potentially leading to surgical downstaging and providing insight into treatment response and prognosis. Neoadjuvant therapies can result in pathologic complete response (pCR), which is predictive of long-term outcomes; patients who attain pCR are consistently found to have better survival outcomes than those with residual disease. Select patients with estrogen receptor positive (ER+) tumors may receive either neoadjuvant chemotherapy (NAC) or neoadjuvant endocrine therapy

APA, Harvard, Vancouver, ISO, and other styles

24

Cucieru, Valerian. "Predictive molecular markers of resistance to chemotherapy in breast cancer." Moldovan Medical Journal 64(1) (February 15, 2021): 68–70. https://doi.org/10.5281/zenodo.4527217.

Full text

Abstract:

Breast cancer is one of the three most common cancers along with lung and colon cancer. It is a leading cause of cancer deaths in both developing and developed countries. Within 2 decades, neoadjuvant chemotherapy (NAC) has become a standard treatment option in breast cancer. Relevant articles were identified by means of PubMed, Embase, Web of Science, Cochrane Library and Springer Link databases published during the years 2010-2019, describing the role of molecular biomarkers in the assessment of NAC for breast cancer. <strong>Conclusions:</strong> The size of the breast primary tumor, the af

APA, Harvard, Vancouver, ISO, and other styles

25

Seiler, Roland, Brian Winters, James Douglas, et al. "Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy." Journal of Clinical Oncology 35, no. 6_suppl (2017): 281. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.281.

Full text

Abstract:

281 Background: Molecular subtypes of muscle-invasive bladder cancers (MIBC) have recently been discovered based on gene expression. We investigated the impact of different subtyping methods on response to neoadjuvant cisplatin-based chemotherapy (NAC) and developed a single sample model for subtyping. Methods: Transcriptome-wide microarray analysis was conducted on pre-NAC transurethral resection (TUR) specimens of 223 patients with MIBC who received NAC followed by cystectomy at 5 centers. The specimens were classified according to four published methods for molecular subtype (UNC, MDA, TCGA

APA, Harvard, Vancouver, ISO, and other styles

26

Simhal, Rishabh Kumar, Kerith Ruoyao Wang, Yash Shah, et al. "Impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes." Journal of Clinical Oncology 41, no. 6_suppl (2023): 575. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.575.

Full text

Abstract:

575 Background: Neoadjuvant chemotherapy (NAC), often with a cisplatin-based regimen, is recommended before radical cystectomy (RC), as studies have shown a modest survival benefit. However, NAC may confer toxicity and augment preoperative frailty, affecting perioperative outcomes. We investigated the relationship between NAC and 30-day RC outcomes using the National Surgical Quality Improvement Program (NSQIP). Methods: RCs performed between 2019-2020 were identified in NSQIP and the corresponding cystectomy-targeted database. Baseline demographics, comorbidities, and operative parameters wer

APA, Harvard, Vancouver, ISO, and other styles

27

Porten, Sima P., Arlene O. Siefker-Radtke, Ashish M. Kamat, Colin P. N. Dinney, and Surena F. Matin. "Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma." Journal of Clinical Oncology 31, no. 6_suppl (2013): 311. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.311.

Full text

Abstract:

311 Background: High-grade upper tract urothelial carcinoma (UTUC) is frequently upstaged at surgery and has uniformly poor survival rates. Neoadjuvant chemotherapy (NAC) may provide an avenue to improve clinical outcomes in these patients prior to loss of renal function after nephroureterectomy. Methods: We performed a retrospective review of patients with high risk UTUC who received NAC followed by surgical extirpation from 2004 to 2008, a time period during which NAC was uniformly offered to patients. The study group was then compared to a historical cohort of similar risk patients who unde

APA, Harvard, Vancouver, ISO, and other styles

28

Oba, Atsushi, Y. H. Andrew Wu, Kathryn L. Colborn, et al. "Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis." British Journal of Surgery 109, no. 5 (2022): 450–54. http://dx.doi.org/10.1093/bjs/znac002.

Full text

Abstract:

Abstract Background Neoadjuvant treatment is important for improving the rate of R0 surgical resection and overall survival outcome in treating patients with pancreatic ductal adenocarcinoma (PDAC). However, the true efficacy of radiotherapy (RT) for neoadjuvant treatment of PDAC is uncertain. This retrospective study evaluated the treatment outcome of neoadjuvant RT in the treatment of PDAC. Methods Collected from the National Cancer Database, information on patients with PDAC who underwent neoadjuvant chemotherapy (NAC) and pancreatectomy between 2010 to 2016 was used in this study. Short- a

APA, Harvard, Vancouver, ISO, and other styles

29

Li, Gang, Hui-min Niu, Hong-tao Wu, et al. "Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis." Clinical & Investigative Medicine 40, no. 2 (2017): 81. http://dx.doi.org/10.25011/cim.v40i2.28199.

Full text

Abstract:

Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) has been shown to improve survival in patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy as compared with patients who underwent surgery alone. It has also been suggested as current standard of care in surgically-fit patients with MIBC. This meta-analysis assessed the effect of cisplatin-based NAC on survival in patients with bladder cancer.   Source: PubMed, CENTRAL, and Embase were searched until November 22, 2016. Two-arm randomized controlled trials that compared cisplatin-based neoadjuvan

APA, Harvard, Vancouver, ISO, and other styles

30

Qodir, Nur, Nurindah Dwi Utami, and Erial Bahar. "Accuracy of a Novel Scoring System for Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients." Sriwijaya Journal of Surgery 4, no. 2 (2021): 240–55. http://dx.doi.org/10.37275/sjs.v4i2.58.

Full text

Abstract:

Background: Neoadjuvant chemotherapy (NAC) has become a widely accepted treatment option for locally advanced breast cancer (LABC). Furthermore, response to NAC is considered to be a predictor of favorable outcomes. It is known that some predictors are associated with NAC response.  Objectives: To assess the accuracy of scoring system for prediction of response to neoadjuvant chemotherapy in LABC. Methods: Medical record of 50 patients received NAC at Mohammad Hoesin Hospital were retrospectively analysed between July 2019 to July 2020. Response of NAC in LABC was determined with R

APA, Harvard, Vancouver, ISO, and other styles

31

Ren, Yulin, Zhenzhen Hui, Liuqing Zheng, et al. "Shift of tumor-infiltrating immune cells after adding immune checkpoint inhibitors to neoadjuvant chemotherapy against NSCLC." Journal of Clinical Oncology 40, no. 16_suppl (2022): e21002-e21002. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21002.

Full text

Abstract:

e21002 Background: Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has revolutionized the treatment strategies in multiple cancer types, including NSCLC. Anti-PD1 combined with chemotherapy was superior to chemotherapy alone, but the fundamental mechanisms underlying their synergic effect remain incompletely understood. Here, we investigated the different effects induced by neoadjuvant pembrolizumab combined with chemotherapy (NAPC) and neoadjuvant chemotherapy (NAC) on tumor immune microenvironment in patients with NSCLC. Methods: We performed single-cell RNA-sequencing (sc

APA, Harvard, Vancouver, ISO, and other styles

32

Viala, Caroline, and Marie Viala. "Response to neoadjuvant chemotherapy in histologic variants of bladder cancer." Journal of Clinical Oncology 40, no. 6_suppl (2022): 458. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.458.

Full text

Abstract:

458 Background: Localized muscle invasive bladder carcinoma is mostly treated with neoadjuvant chemotherapy (NAC) before surgery in order to improve the outcome. Urothelial carcinoma (UC) is the most frequent histological type. Histological variants (pure or mixed) occur in 10% of bladder carcinoma. There is a lack of data on NAC efficacy for these histological subtypes. In this study, we evaluated the histologic response to NAC in the variant population of bladder cancer. Methods: Patients from 2 french hospitals (CHU de Nantes and ICM) treated with NAC for bladder cancer from 2010 to August

APA, Harvard, Vancouver, ISO, and other styles

33

Lim, Kylie Yen-Yi, Kevin Chu, Nieroshan Rajarubendra, et al. "Patterns of chemotherapy use in muscle-invasive bladder cancer in a tertiary centre." Bladder 10 (December 11, 2023): e21200013. http://dx.doi.org/10.14440/bladder.2023.872.

Full text

Abstract:

Objectives: Although neoadjuvant chemotherapy (NAC) has been demonstrated to have significant benefits to survival in patients with muscle-invasive bladder cancer (MIBC), the current utilization of NAC in Australia is unknown. The aim of this study was to evaluate the patterns of neoadjuvant and adjuvant chemotherapy (AC) use in patients undergoing cystectomy for MIBC at a large tertiary institution in Australia. Methods: A retrospective study was conducted using data of patients who underwent a radical cystectomy (RC) at a high-volume centre for MIBC between 2011 and 2021. Results: Of 69 pati

APA, Harvard, Vancouver, ISO, and other styles

34

Sundi, Debasish. "Pathways Forward in Candidate Selection for Systemic Therapy in Invasive Urothelial Cancer of the Bladder." Oncology & Hematology Review (US) 12, no. 01 (2016): 49. http://dx.doi.org/10.17925/ohr.2016.12.01.49.

Full text

Abstract:

Neoadjuvant chemotherapy (NAC) prior to radical cystectomy improves overall survival for patients with invasive bladder cancer, compared to patients undergoing radical cystectomy alone. However, only a subset of patients benefit from NAC. This editorial highlights recent and emerging developments that aim to identify optimal NAC candidates.

APA, Harvard, Vancouver, ISO, and other styles

35

Xing, Eunice Yun, and Naveed Sarwar. "Muscle-invasive Bladder Cancer: How to Select Patients for Neoadjuvant Chemotherapy." UroCancer Clinics of India 2, no. 2 (2024): 85–90. http://dx.doi.org/10.4103/ucci.ucci_16_24.

Full text

Abstract:

Summary Approximately 25% of patients with bladder cancer present with muscle-invasive disease. International guidelines recommend cisplatin-based neoadjuvant chemotherapy (NAC) for patients suitable for radical treatment. However, appropriate candidate selection for NAC is crucial to ensure that the benefits outweigh potential toxicities and delays to radical cystectomy (RC). Patients should meet eligibility criteria for cisplatin therapy, and factors such as age, comorbidities, and nutritional status should be evaluated in conjunction. Timely initiation of NAC following diagnosis is essentia

APA, Harvard, Vancouver, ISO, and other styles

36

Alva-Ruiz, Roberto, Lavanya Yohanathan, Jennifer A. Yonkus, et al. "Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer." Annals of Surgical Oncology 29, no. 3 (2021): 1579–91. http://dx.doi.org/10.1245/s10434-021-10991-2.

Full text

Abstract:

Abstract Background Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). The identification of a chemotherapeutic regimen that is both effective and tolerable is critical for NAC to be of oncologic benefit. After initial first-line (FL) NAC, some patients have lack of response or therapeutic toxicities precluding further treatment with the same regimen; optimal decision making regarding this patient population is unclear. Chemotherapy switch (CS) may allow for a lar

APA, Harvard, Vancouver, ISO, and other styles

37

Wang, Kerith Ruoyao, Rishabh Simhal, Yash Shah, et al. "The impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes." Journal of Clinical Oncology 41, no. 16_suppl (2023): 4594. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4594.

Full text

Abstract:

4594 Background: Neoadjuvant chemotherapy (NAC), often a cisplatin-based regimen, is recommended before radical cystectomy (RC), as studies have shown a modest survival benefit. However, NAC may confer toxicity and augment preoperative frailty, affecting perioperative outcomes. We investigated the relationship between NAC and 30-day RC outcomes using the National Surgical Quality Improvement Program (NSQIP). Methods: RCs performed between 2019-2020 were identified in NSQIP and the corresponding cystectomy-targeted database. Baseline demographics, comorbidities, and operative parameters were co

APA, Harvard, Vancouver, ISO, and other styles

38

Dip Borunda, Abdel Karim, Eucario Leon Rodriguez, and Alejandra Armengol Alonso. "Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer: Experience in Mexican population." Journal of Clinical Oncology 30, no. 15_suppl (2012): e15567-e15567. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15567.

Full text

Abstract:

e15567 Background: Primary debulking surgery is considered the standard of treatment in advanced ovarian cancer (AOC) while neoadjuvant chemotherapy is used in non resectable stages. Methods: We retrospectively analyzed 68 AOC cases from January 2000 to December 2011. 35 received neoadjuvant chemotherapy (NAC) while 33 were resected primarily and received adjuvant chemotherapy (AC). To compare both groups we used T standard test and 2 sided chi -squared. Non parametric variables were analyzed with U Mann – Whitney. Overall survival(OS) was analyzed using Kaplan Meier method with log rank test.

APA, Harvard, Vancouver, ISO, and other styles

39

Saito, Kei, Yousuke Nakai, Yoshihiro Sakamoto, et al. "Did neoadjuvant chemotherapy provide better long term outcomes in borderline resectable with arterial involvement (BR-A PC)?" Journal of Clinical Oncology 36, no. 4_suppl (2018): 434. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.434.

Full text

Abstract:

434 Background: Recently high rates of conversion (or adjuvant) surgery were reported after neoadjuvant chemo(radiation)therapy (NAC) for borderline or locally advanced pancreatic cancer (BR/LA PC) including our phase II trial of gemcitabine, S-1 and leucovorin (GSL) combination therapy for BR PC with arterial involvement (BR-A PC) and LA PC. In our phase II trial, a high recurrence rate of 78% was noted despite a high R0 resection of 76%. Herein, we conducted a retrospective analysis of BR-A PC who underwent NAC, upfront surgery and palliative chemotherapy to evaluate the long term outcomes o

APA, Harvard, Vancouver, ISO, and other styles

40

Matsumoto, Noriko. "Investigation of thrombospondin 1 (THBS1) as prognostic and predictive factor of neoadjuvant chemotherapy for advanced gastric cancer." Journal of Clinical Oncology 31, no. 4_suppl (2013): 49. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.49.

Full text

Abstract:

49 Background: Curative R0 operation is the best treatment for patients with Stage II/III gastric cancer, but still there are recurrent cases. Although chemotherapy is an important treatment, there is no evidence of neoadjuvant chemotherapy (NAC) for both R0 operated advanced gastric cancer and inoperable cases. Thrombospondin 1 (THBS1) plays a role in angiogenesis in many cancers, and we reported that THBS1 could be prognostic factor of Stage IV gastric cancer and predictive factor of S-1+ paclitaxel chemotherapy. The aim of this study is to investigate THBS1 plays as prognostic and predictiv

APA, Harvard, Vancouver, ISO, and other styles

41

de Jong, D., J. E. Dodge, O. Freedman, E. Lo, B. P. Rosen, and H. Mackay. "Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma." Journal of Clinical Oncology 27, no. 15_suppl (2009): 5512. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5512.

Full text

Abstract:

5512 Background: Neoadjuvant chemotherapy (NAC) is increasingly used to treat patients (pts) with presumed advanced-stage epithelial ovarian cancer (EOC) who are deemed ineligible for upfront debulking surgery (DS). DS following NAC offers a survival benefit to those pts in whom optimal cytoreduction (< 1 cm residual tumor) is achieved. However, not all women who commence NAC have a subsequent attempt at DS. The aims of this study were to identify, in pts planned for NAC, predictive parameters for attempting DS and for achieving optimal cytoreduction in those undergoing surgery. Methods: Pt

APA, Harvard, Vancouver, ISO, and other styles

42

Stiff, Andrew, Christopher McQuinn, Robert Wesolowski, et al. "Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e12126-e12126. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12126.

Full text

Abstract:

e12126 Background: Even with neo-adjuvant chemotherapy (NAC) many breast cancer (BC) patients (pts) relapse, especially triple negative pts. The incorporation of checkpoint inhibitors into NAC for BC is being tested in clinical trials. How NAC affects checkpoint receptor expression is not known. Such information could aid in the rational selection of checkpoints to target during NAC. We sought to characterize changes in the frequency of circulating CD4 and CD8 T cells expressing PD1, CTLA4, LAG3, TIM3, and OX40 over the course of NAC. Methods: In this prospective trial, expression of PD-1, CTL

APA, Harvard, Vancouver, ISO, and other styles

43

Lee, Suji, Jee Yeon Kim, So Jeong Lee, et al. "Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer." Medicina 60, no. 5 (2024): 737. http://dx.doi.org/10.3390/medicina60050737.

Full text

Abstract:

Background and Objectives: This study aimed to explore biomarker change after NAC (neoadjuvant chemotherapy) and to investigate biomarker expression as a prognostic factor in patients with residual disease (RD) after NAC. Materials and Methods: We retrospectively evaluated 104 patients with invasive breast cancer, who underwent NAC and surgery at Pusan National University Hospital from 2015 to July 2022. The expression of the biomarker was assessed, and the overall survival (OS) and disease-free survival (DFS) were investigated. Results: After NAC, 24 patients (23.1%) out of 104 total patients

APA, Harvard, Vancouver, ISO, and other styles

44

Cowan, N. G., Y. Chen, T. M. Downs, et al. "Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions." Advances in Urology 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/746298.

Full text

Abstract:

Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low. The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists.Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed.Results.

APA, Harvard, Vancouver, ISO, and other styles

45

Čižauskaitė, Agnė, Donatas Petrauskas, Dainius Šimčikas, and Alvydas Česas. "Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy. It Is Worth To Decide!" Sveikatos mokslai 26, no. 5 (2016): 84–87. http://dx.doi.org/10.5200/sm-hs.2016.077.

Full text

Abstract:

Objective. To evaluate the predictable percentage of patients that could be eligible for sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in Klaipeda University Hospital Breast Surgery Department. Background. Although SLNB is a standard staging method for axillar node status assessment for early- stage clinically lymph node (LN) negative breast cancer patients, SLNB after NAC is still controversial. Axillary lymph node dissection (ALND) still remains standard accepted surgical approach for patients following NAC regardless of primary LN status. ALND is associated with sig

APA, Harvard, Vancouver, ISO, and other styles

46

Laas, Enora, Arnaud Bresset, Jean-Guillaume Féron, et al. "HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens." Cancers 13, no. 3 (2021): 370. http://dx.doi.org/10.3390/cancers13030370.

Full text

Abstract:

Background: No survival benefit has yet been demonstrated for neoadjuvant chemotherapy (NAC) against HER2-positive tumors in patients with early breast cancer (BC). The objective of this study was to compare the prognosis of HER2-positive BC patients treated with NAC to that of patients treated with adjuvant chemotherapy (AC). Materials and methods: We retrospectively analyzed disease-free (DFS) and overall survival (OS) in 202 HER2-positive patients treated with NAC and 701 patients treated with AC. All patients received trastuzumab in addition to chemotherapy. Patient data were weighted by a

APA, Harvard, Vancouver, ISO, and other styles

47

Zhang, Wei, Emma Li, Lily Wang, Brian D. Lehmann, and X. Steven Chen. "Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy." Cancers 15, no. 8 (2023): 2194. http://dx.doi.org/10.3390/cancers15082194.

Full text

Abstract:

Triple-negative breast cancer (TNBC) is a heterogeneous disease with varying responses to neoadjuvant chemotherapy (NAC). The identification of biomarkers to predict NAC response and inform personalized treatment strategies is essential. In this study, we conducted large-scale gene expression meta-analyses to identify genes associated with NAC response and survival outcomes. The results showed that immune, cell cycle/mitotic, and RNA splicing-related pathways were significantly associated with favorable clinical outcomes. Furthermore, we integrated and divided the gene association results from

APA, Harvard, Vancouver, ISO, and other styles

48

Soraya, Sami sahnoun. "Neoadjuvant chemotherapy in locally advanced breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (2012): e11034-e11034. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e11034.

Full text

Abstract:

e11034 Background: Neoadjuvant chemotherapy(NAC)is one of the treatment options for locally advanced breast cancer. In this study, we evaluated the efficacy and safety of 4 cycles of NAC doxorubicine,docetaxel and cyclophosphamide(TAC),correlation between the response to NAC and molecular classification sub-groups and between the pCR and the time to progression(TTP). Methods: This is a prospective study from January 2005 to December 2008.110 pts with locally advanced breast cancer stage III.All pts have received 4 cycles of NAC based on docetaxel 75 mg/m², doxorubicine 50 mg/m² and cyclophosph

APA, Harvard, Vancouver, ISO, and other styles

49

Brant, Aaron, Max Kates, Meera Chappidi, Hiten D. Patel, Nikolai A. Sopko, and Trinity J. Bivalacqua. "Effect of chemotherapy and/or TURBT on pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer." Journal of Clinical Oncology 34, no. 2_suppl (2016): 395. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.395.

Full text

Abstract:

395 Background: Neoadjuvant chemotherapy (NAC) for muscle−invasive bladder cancer (MIBC) has been associated with a survival benefit in patients who achieve pathologic response. However, a smaller but significant group of patients who receive transurethral resection of bladder tumor (TURBT) without NAC will also be down−staged. We estimated the prevalence of pathologic response to TURBT in patients who receive NAC. Methods: Of 737 serial patients who received radical cystectomy (RC) at Johns Hopkins Medical Center from 2005–2014, 328 with cT2 urothelial carcinoma were identified. 172 patients

APA, Harvard, Vancouver, ISO, and other styles

50

Zheng, Chunhui, Yongsheng Wang, Yingxue Qi, Yunjie Song, Xiangyu Yin, and Ningning Luo. "A propensity-matched cohort study of neoadjuvant immunotherapy combined with chemotherapy versus neoadjuvant chemotherapy for early-stage triple-negative breast cancer." Journal of Clinical Oncology 42, no. 16_suppl (2024): e13134-e13134. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e13134.

Full text

Abstract:

e13134 Background: Preferred neoadjuvant treatment (NAT) regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. This study compared the efficacy, safety and biomarker exploration of camrelizumab combined with chemotherapy and chemotherapy as neoadjuvant treatment for early-stage TNBC. Methods: This study included 2 cohorts with different NAT regimens, matched (2:1) according to age, clinical T and N stage, and Ki-67 status. Patients in the immune combination chemotherapy (NIC) cohort were recruited from a phase II cli

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!